Associated Papers
Ultrasensitive analysis of genetic instability related to chemical exposure.
Domoradzki T et al.
Journal of Applied Genetics, 2022
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.
Felsenstein KM et al.
Nature Reviews. Urology, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Lee MS et al.
Cancer Research and Treatment, 2017
Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
Kobayashi-Watanabe N et al.
Lung Cancer (amsterdam, Netherlands), 2017
The evolving genomic landscape of urothelial carcinoma.
Glaser AP et al.
Nature Reviews. Urology, 2017
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Terashima M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
Terai H et al.
Acs Chemical Biology, 2015
Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.
Takeda M et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2015
NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
Xu C et al.
Molecular Cancer Therapeutics, 2015
Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
Bai Y et al.
Cancer Research, 2014
Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M et al.
Medical Oncology (northwood, London, England), 2014
Tongue carcinoma infrequently harbor common actionable genetic alterations.
Tan DS et al.
Bmc Cancer, 2014
Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
Payne LS et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Okamoto I et al.
Oncotarget, 2014
Collagen recognition and transmembrane signalling by discoidin domain receptors.
Carafoli F et al.
Biochimica Et Biophysica Acta, 2013
Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
Iwai LK et al.
The Biochemical Journal, 2013
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS et al.
Cancer Discovery, 2011